Preclinical Data On AngioChem Pain Program Published In Journal Of Clinical Investigation
2/18/2014 9:58:18 AM
MONTREAL--(BUSINESS WIRE)--Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced that its neuropeptide conjugate, ANG2002, a new chemical entity formed by conjugation of the peptides Angiopep-2 (An2) and neurotensin, successfully crosses the BBB to achieve therapeutic concentrations in the brain. Analgesic efficacy was demonstrated at low systemic doses of ANG2002 in rat models of neuropathic, inflammatory, and cancer pain, this efficacy was associated with a good safety profile. Despite its non-opiate mechanism, ANG2002 analgesic efficacy is similar to that of morphine. Furthermore, these results underscore the potential of the company’s technology to develop novel biologic therapeutics that crosses the BBB for CNS-related indications.
Help employers find you! Check out all the jobs and post your resume.
comments powered by